Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

SITRANSPORTER

Financiado

Cerrado

Identification of molecular transporters that facilitate siRNA skin delivery

The ability to target gene expression with nucleic acid-based therapeutics including small interfering RNAs (siRNAs) has opened up novel treatment opportunities for genetic skin disorders. Although siRNAs have exquisite selectivit... ver más

31/03/2016

UNIVDUN

300K€

Presupuesto del proyecto: 300K€

Líder del proyecto

UNIVERSITY OF DUNDEE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2016-03-31 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

UNIVDUN

0.00€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

mRNA NanoDeli Application of RNA nanotechnology for delivery of mRNA thera... 90K€ Cerrado

TACIT Targeted Amphoteric Carriers in ImmunoTherapy 961K€ Cerrado

PDC2021-121192-I00 UNA NUEVA PLATAFORMA QUIMICA PARA TERAPIA GENICA A LA CARTA 144K€ Cerrado

RNAI IN HSC VIA NP Delivery of siRNAs to hematopoietic stem cells using nanopar... 100K€ Cerrado

grabRNA Smart RNA delivery for therapy and diagnostic 150K€ Cerrado

inteRNAlizer Efficient, safe, and cost-efficient RNA delivery vehicles fo... 150K€ Cerrado

Líder del proyecto

UNIVERSITY OF DUNDEE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 300K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The ability to target gene expression with nucleic acid-based therapeutics including small interfering RNAs (siRNAs) has opened up novel treatment opportunities for genetic skin disorders. Although siRNAs have exquisite selectivity and potency, translation to the clinic has been hampered due to the lack of efficient delivery systems that allow penetration through the outer barrier of the skin, the stratum corneum, and uptake by the live cells of the dermis and epidermis. A number of physical and chemical methods have been used to deliver siRNA across the stratum corneum into the epidermis. Once in the tissue, the target cells must internalize the siRNA. Self-delivery siRNAs have been identified that obviate the need for transfection reagents and are widely used in vitro. However, cellular uptake of the most effective self-delivery siRNAs is still inefficient compared to siRNA complexed with transfection reagents. Other functionalities may enhance delivery, but screening large numbers of modifications for self-delivery properties is hindered by cumbersome RNA synthesis methods. The long-term goal of this project is to develop novel siRNA conjugates that will facilitate optimal delivery to the affected tissues and cells for treatment of genetic disorders, particularly those of the skin. Here, it is proposed to develop an efficient method for conjugating siRNAs to a library of small molecules. The proposed strategy takes advantage of standard thiol and amine chemistries, producing a stable, covalent crosslink between the siRNA and any molecule containing a primary amine. These conjugates will initially be screened using a keratinocyte cell line expressing a reporter gene. In preparation for translation to the clinic, lead inhibitors will be fully characterized and tested for their ability to specifically inhibit reporter and endogenous gene expression in vitro and in vivo.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores